Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CYTOKINETICS, INCORPORATED

(CYTK)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
41.06 USD   -4.78%
01/17Goldman Sachs Adjusts Price Target on Cytokinetics to $56 From $47, Maintains Buy Rating
MT
01/12Insider Sell: Cytokinetics
MT
01/09Transcript : Cytokinetics, Incorporated Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CYTOKINETICS INC : Other Events (form 8-K)

12/07/2022 | 07:35am EST

Item 8.01 Other Events.

On December 7, 2022, Cytokinetics, Incorporated announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of CK-3828136 (CK-136), formerly known as AMG 594. CK-136 is a cardiac troponin activator, discovered under a previous joint research program with Amgen Inc. (Amgen), in development for the potential treatment of patients with heart failure with reduced ejection fraction (HFrEF) and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility.

Phase 1 Clinical Trial Design

The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose trial is to assess the safety, tolerability and pharmacokinetics of CK-136 when administered orally as single or multiple doses to healthy participants. The study design includes three groups of at least eight participants in single ascending dose cohorts and four groups of at least eight participants in multiple-dose ascending cohorts. A final optional cohort will include eight participants in an open-label, 2-period crossover arm to investigate the effect of food on CK-136.

About CK-3828136

CK-3828136 (CK-136) is a novel, selective, oral, small molecule cardiac troponin activator. In preclinical models, CK-136 increased myocardial contractility by binding to cardiac troponin through an allosteric mechanism that sensitizes the cardiac sarcomere to calcium, facilitating more actin-myosin cross bridge formation during each cardiac cycle thereby resulting in increased myocardial contractility. Similar to cardiac myosin activation, preclinical research has shown that cardiac troponin activation does not change the calcium transient of cardiac myocytes. Development of CK-136 may include the evaluation of this novel mechanism of action as a potential treatment of patients with heart failure with reduced ejection fraction (HFrEF) and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility. Under our prior collaboration, Amgen previously conducted a randomized, placebo-controlled, double-blind, single and multiple ascending dose, single-center Phase 1 study to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of CK-136 in healthy subjects.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-in-class cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, relating to the potential benefits of CK-136 for patients with heart failure with reduced ejection fraction (HFrEF) and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or -------------------------------------------------------------------------------- product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about CYTOKINETICS, INCORPORATED
01/17Goldman Sachs Adjusts Price Target on Cytokinetics to $56 From $47, Maintains Buy Ratin..
MT
01/12Insider Sell: Cytokinetics
MT
01/09Transcript : Cytokinetics, Incorporated Presents at 41st Annual J.P. Morgan H..
CI
01/09Cytokinetics Inc : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/06Insider Sell: Cytokinetics
MT
01/04Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
01/03Cytokinetics to Participate in theá41st Annual J.P. Morgan Healthcare Conference
AQ
2022Needham Cuts Price Target on Cytokinetics to $58 From $60, Keeps Buy Rating
MT
2022Truist Securities Initiates Cytokinetics With Buy Rating, Price Target is $60
MT
2022Goldman Sachs Adjusts Price Target on Cytokinetics to $47 From $55, Maintains Buy Ratin..
MT
More news
Analyst Recommendations on CYTOKINETICS, INCORPORATED
More recommendations
Financials (USD)
Sales 2022 99,6 M - -
Net income 2022 -367 M - -
Net Debt 2022 36,6 M - -
P/E ratio 2022 -10,6x
Yield 2022 -
Capitalization 4 080 M 4 080 M -
EV / Sales 2022 41,3x
EV / Sales 2023 99,2x
Nbr of Employees 253
Free-Float 95,6%
Chart CYTOKINETICS, INCORPORATED
Duration : Period :
Cytokinetics, Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTOKINETICS, INCORPORATED
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 43,12 $
Average target price 62,67 $
Spread / Average Target 45,3%
EPS Revisions
Managers and Directors
Robert I. Blum CFO, SVP-Corporate Development & Finance
Ching W. Jaw Chief Financial Officer & Senior Vice President
John Tannahill Henderson Chairman
Andrew A. Wolff Senior VP-Clinical Research & Development
Fady Ibraham Malik Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CYTOKINETICS, INCORPORATED-5.89%4 080
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
WUXI APPTEC CO., LTD.18.94%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008